HRT Safety: The 2-Year Evidence Consensus
Executive Summary
A definitive guide to the current clinical understanding of Hormone Replacement Therapy risks and benefits.
If you're under 60 and struggling with symptoms, the 'scary' headlines from 20 years ago likely don't apply to you. Modern HRT uses 'body-identical' hormones that are much gentler than the synthetic ones used in the past. It’s not just about stopping hot flashes; it’s about 'insurance' for your heart and bones as you age.
Clinical Brief
Current meta-analyses of over 20 years of data (post-WHI) indicate that the 'Timing Hypothesis' is critical. Initiating HRT before age 60 or within 10 years of menopause onset shows a significant reduction in all-cause mortality and fractures. Concerns regarding breast cancer risk are now stratified by formulation: micronized progesterone and transdermal estradiol show the lowest risk profiles in recent observational studies.
Key Evidence Points
Body-identical transdermal estradiol does not increase blood clot risk.
Early initiation (under 60) reduces cardiovascular event risk.
Breast cancer risk with HRT is lower than the risk associated with daily alcohol consumption or obesity.
Bone density is significantly preserved, reducing later-life fracture risk.